Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3559682 Target Snapshot

Serine/threonine-protein kinase PIM · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
104Compounds
19Assays
0Approved Drugs
102.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Serine/threonine-protein kinase PIM shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P11309. Start with acute myeloid leukemia, then reuse UniProt P11309 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acute myeloid leukemia, then reuse UniProt P11309 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
acute myeloid leukemia

Serine/threonine-protein kinase PIM shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include AZD-1208, LGH-447. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase PIM as ChEMBL target CHEMBL3559682, mapped to UniProt P11309. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase PIM
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3559682
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P11309
Serine/threonine-protein kinase pim-1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase PIM is the right protein anchor across sources, using UniProt P11309 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acute myeloid leukemia is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSerine/threonine-protein kinase PIM
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP11309
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase pim-1
UniProt AccessionP11309
Component TypeProtein
Sequence Length313 aa

Serine/threonine-protein kinase pim-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase PIM, mapped to UniProt P11309. ChEMBL maps the protein component as Serine/threonine-protein kinase pim-1. Sequence length is 313 aa.

Mapped IDP11309
Review nameSerine/threonine-protein kinase PIM
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Serine/threonine-protein kinase PIM shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.

Clinical signal Phase I
acute myeloid leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZD-1208
Linked drugLGH-447
Clinical signal Phase I
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD-1208
Clinical signal Phase I
leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSGI-1776
Clinical signal Phase I
lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD-1208
Clinical signal Phase I
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugLGH-447
Clinical signal Phase I
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugLGH-447
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include AZD-1208, LGH-447. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacute myeloid leukemia
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5075.0
EC5027.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3950704 7.96 IC50 11.0 Preclinical
CHEMBL4593810 7.89 EC50 13.0 Preclinical
CHEMBL3809940 7.85 IC50 14.0 Preclinical
CHEMBL3808662 7.8 IC50 16.0 Preclinical
CHEMBL4448325 7.75 EC50 18.0 Preclinical
CHEMBL3808669 7.7 IC50 20.0 Preclinical
CHEMBL3808887 7.7 IC50 20.0 Preclinical
CHEMBL3810121 7.68 IC50 21.0 Preclinical
CHEMBL4541192 7.66 IC50 22.0 Preclinical
CHEMBL4587596 7.64 IC50 23.0 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
11
5.5
8
6.0
17
6.5
24
7.0
22
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

19
Total Assays
88
Tested Compounds
1
Assay Types
Binding — 19 assays, 88 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 16 88 6.8
protein format 3 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine